Adial Pharmaceuticals Awarded New AD04 Patent For Genotype-Specific Treatment Of Opioid-Related Disorders

Adial Pharmaceuticals, Inc. (Adial), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced patent number 12,221,654 was issued on February 11, 2025, by the United States Patent and Trademark Office. This patent expands the covered methods of identifying patients with specific genetic markers linked to substance use disorders and treating them with AD04, the Company’s investigational new drug product. The treatment approach involves detecting the TT genotype of rs1042173 in the serotonin transporter gene (SLC6A4) and administering AD04. These treatment methods are tailored for individuals suffering . . .